Daijiworld Media Network - Chicagο
Chicagο, Mar 7: A preliminary study conducted by researchers in Brazil and the United States suggests that GLP-1 medications used for weight loss, such as Ozempic and Wegovy, may help reduce emergency room visits and hospitalisations among people with chronic migraine compared with traditional preventive treatment with topiramate.
According to the study, which will be presented at the American Academy of Neurology Annual Meeting in April 2026, individuals taking GLP-1 drugs were 10% less likely to visit the ER, 14% less likely to be hospitalised, and around 13% less likely to need procedures like nerve blocks or receive triptan prescriptions than those on topiramate.
The study analysed medical records of approximately 11,000 patients in each group, matched for age, BMI, prior migraine treatments, and other health conditions. GLP-1 medications included liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, and albiglutide.
Researchers also found that GLP-1 users were less likely to start new preventive migraine medications:
48% less likely to start valproate
42% less likely to start CGRP monoclonal antibodies
35% less likely to start tricyclic antidepressants
23% less likely to start gepants
Dr. Hsiangkuo (Scott) Yuan of Thomas Jefferson University said mechanisms behind the benefits may include anti-inflammatory effects, reduced cerebrospinal fluid pressure, and modulation of migraine-promoting signaling molecules like CGRP. He also noted that weight loss itself may improve migraine outcomes.
Experts caution, however, that the findings are observational and do not prove causation. Dr. Medhat Mikhael, pain management specialist, stressed that GLP-1 drugs should not be used solely for migraine prevention outside of clinical trials.
Migraine affects 148 million people worldwide, including 37 million in the US, and is one of the top 10 most disabling conditions globally. Chronic migraine is defined as having 15 or more headache days per month over three months, with at least eight days showing migraine features like aura, nausea, or light and sound sensitivity.
Current management focuses on symptom relief and prevention, including rest, hydration, short-term medications like triptans or over-the-counter pain relievers, and preventive drugs such as anticonvulsants, beta-blockers, calcium channel blockers, and antidepressants.
The study’s encouraging signals warrant further investigation through large-scale clinical trials to evaluate the safety and effectiveness of GLP-1 medications in migraine management.